{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:15:46Z","timestamp":1791281746881,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1016\/j.ymgme.2011.02.004","type":"journal-article","created":{"date-parts":[[2011,2,12]],"date-time":"2011-02-12T06:32:27Z","timestamp":1297492347000},"page":"1-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":129,"title":["Pompe disease: Design, methodology, and early findings from the Pompe Registry"],"prefix":"10.1016","volume":"103","author":[{"given":"Barry J.","family":"Byrne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya S.","family":"Kishnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E.","family":"Case","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Merlini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"M\u00fcller-Felber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyash","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ans van","family":"der Ploeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2011.02.004_bb0005","unstructured":"R. Hirschhorn, A.J.J. Reuser, Glycogen storage disease type II: Acid alpha-glucosidase (acid maltase) deficiency, in: D. Valle, A.L. Beaudet, B. Vogelstein, K.W. Kinzler, S.E. Antonarakis, A. Ballabio (Eds.), The Metabolic & Molecular Bases of Inherited Disease, McGraw-Hill, New York (2001)."},{"key":"10.1016\/j.ymgme.2011.02.004_bb0010","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1093\/hmg\/ddn292","article-title":"Suppression of autophagy in skeletal muscle uncovers the accumulation of ubiquitinated proteins and their potential role in muscle damage in Pompe disease","volume":"17","author":"Raben","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2011.02.004_bb0015","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2011.02.004_bb0020","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1542\/peds.112.2.332","article-title":"The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature","volume":"112","author":"van den Hout","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2011.02.004_bb0025","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/brain\/awh384","article-title":"Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients","volume":"128","author":"Hagemans","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.ymgme.2011.02.004_bb0030","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.nmd.2007.06.002","article-title":"Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients","volume":"17","author":"Muller-Felber","year":"2007","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymgme.2011.02.004_bb0035","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","article-title":"Pompe disease diagnosis and management guideline","volume":"8","author":"Kishnani","year":"2006","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2011.02.004_bb0040","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/j.1469-8749.2003.tb00966.x","article-title":"Pompe disease and physical disability","volume":"45","author":"Haley","year":"2003","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.ymgme.2011.02.004_bb0045","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1212\/01.wnl.0000252798.25690.76","article-title":"Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype","volume":"68","author":"Kroos","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2011.02.004_bb0050","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.rmed.2008.12.009","article-title":"Pompe disease: a neuromuscular disease with respiratory muscle involvement","volume":"103","author":"Mellies","year":"2009","journal-title":"Respir. Med."},{"key":"10.1016\/j.ymgme.2011.02.004_bb0055","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00415-005-0922-9","article-title":"The natural course of non-classic Pompe's disease; a review of 225 published cases","volume":"252","author":"Winkel","year":"2005","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2011.02.004_bb0060","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/mus.21025","article-title":"Clinical features of late-onset Pompe disease: a prospective cohort study","volume":"38","author":"Wokke","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymgme.2011.02.004_bb0065","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1212\/WNL.57.7.1290","article-title":"Sleep-disordered breathing and respiratory failure in acid maltase deficiency","volume":"57","author":"Mellies","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2011.02.004_bb0070","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00415-005-0922-9","article-title":"The natural course of non-classic Pompe's disease; a review of 225 published cases","volume":"252","author":"Winkel","year":"2005","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2011.02.004_bb0075","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1212\/01.wnl.0000198776.53007.2c","article-title":"Course of disability and respiratory function in untreated late-onset Pompe disease","volume":"66","author":"Hagemans","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2011.02.004_bb0080","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2011.02.004_bb0085","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2011.02.004_bb0090","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/GIM.0b013e31819d0996","article-title":"Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease","volume":"11","author":"Nicolino","year":"2009","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2011.02.004_bb0095","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1203\/PDR.0b013e3181b24e94","article-title":"Early treatment with alglucosidase alfa prolongs long term survival of infants with Pompe disease","volume":"66","author":"Kishnani","year":"2009","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgme.2011.02.004_bb0100","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s10545-010-9206-3","article-title":"Treatment of infantile Pompe disease with alglucosidase alpha: the UK experience","volume":"33","author":"Chakrapani","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2011.02.004_bb0105","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ymgme.2008.09.001","article-title":"Improvement with ongoing Enzyme Replacement Therapy in advanced late-onset Pompe disease: a case study","volume":"95","author":"Case","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2011.02.004_bb0110","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s11606-009-0923-y","article-title":"Visual Hallucinations in a Patient with Adult Onset Acid Maltase Deficiency Disorder","volume":"24","author":"Patil","year":"2009","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.ymgme.2011.02.004_bb0115","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1007\/s12325-008-0086-y","article-title":"Enzyme replacement therapy in severe adult-onset glycogen storage disease type II","volume":"25","author":"Ravaglia","year":"2008","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ymgme.2011.02.004_bb0120","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1468-1331.2008.02377.x","article-title":"Glycogen storage disease type II (Pompe disease) \u2014 influence of enzyme replacement therapy in adults","volume":"16","author":"Merk","year":"2009","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ymgme.2011.02.004_bb0125","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.nmd.2008.04.009","article-title":"Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease","volume":"18","author":"van Capelle","year":"2008","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymgme.2011.02.004_bb0130","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/ana.20019","article-title":"Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up","volume":"55","author":"Winkel","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymgme.2011.02.004_bb0135","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1756285609103324","article-title":"Progress in enzyme replacement therapy in glycogen storage disease type II","volume":"2","author":"Angelini","year":"2009","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.ymgme.2011.02.004_bb0140","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00415-009-5275-3","article-title":"Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial","volume":"257","author":"Strothotte","year":"2010","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2011.02.004_bb0145","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A randomized study of alglucosidase alfa in late-onset Pompe's disease","volume":"362","author":"van der Ploeg","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2011.02.004_bb0150","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1212\/01.WNL.0000165979.46537.56","article-title":"Disease severity in children and adults with Pompe disease related to age and disease duration","volume":"64","author":"Hagemans","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2011.02.004_bb0155","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.nmd.2007.06.115","article-title":"Gradual disease progression during long-term follow up of patients with late-onset Pompe disease [abtract]","volume":"17","author":"Van der Beek","year":"2007","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymgme.2011.02.004_bb0160","first-page":"42","article-title":"The challenges associated with developing therapies for rare diseases","volume":"1","author":"Prasad","year":"2009","journal-title":"Br. J. Med. Procurement"},{"key":"10.1016\/j.ymgme.2011.02.004_bb0165","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1001\/archinte.160.18.2835","article-title":"The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease","volume":"160","author":"Charrow","year":"2000","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ymgme.2011.02.004_bb0170","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","article-title":"Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry","volume":"30","author":"Eng","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2011.02.004_bb0175","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ymgme.2007.01.011","article-title":"The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type I","volume":"91","author":"Pastores","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2011.02.004_bb0180","article-title":"When Clinical Trials Aren' t Enough","author":"Gliklich","year":"2008","journal-title":"Appl. Clin. Trials"},{"key":"10.1016\/j.ymgme.2011.02.004_bb0185","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/mus.21376","article-title":"Screening for Pompe disease using a rapid dried blood spot method: experience of a clinical diagnostic laboratory","volume":"40","author":"Goldstein","year":"2009","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymgme.2011.02.004_bb0190","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1177\/0883073809356035","article-title":"Screening of Late-Onset Pompe Disease in a Sample of Mexican Patients With Myopathies of Unknown Etiology: Identification of a Novel Mutation in the Acid {alpha}-Glucosidase Gene","volume":"25","author":"Alcantara-Ortigoza","year":"2010","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.ymgme.2011.02.004_bb0195","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ymgme.2011.02.004_bb0200","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"3389","article-title":"Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency","author":"Hirschhorn","year":"2001"},{"key":"10.1016\/j.ymgme.2011.02.004_bb0205","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe's disease","volume":"372","author":"van der Ploeg","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2011.02.004_bb0210","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/mus.21393","article-title":"Diagnostic criteria for late-onset (childhood and adult) Pompe disease","volume":"40","author":"AANEM","year":"2009","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymgme.2011.02.004_bb0215","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ymgme.2006.12.006","article-title":"Rapid diagnosis of late-onset Pompe disease by fluorometric assay of alpha-glucosidase activities in dried blood spots","volume":"90","author":"Kallwass","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2011.02.004_bb0220","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1542\/peds.2007-2222","article-title":"Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program","volume":"122","author":"Chien","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2011.02.004_bb0225","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ymgme.2007.09.006","article-title":"Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting","volume":"93","author":"Winchester","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2011.02.004_bb0230","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1365-2990.2007.00839.x","article-title":"Adult-onset glycogen storage disease type 2: clinico-pathological phenotype revisited","volume":"33","author":"Schoser","year":"2007","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.ymgme.2011.02.004_bb0235","first-page":"132","article-title":"Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I\/II clinical trial","volume":"3","author":"Amalfitano","year":"2001","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2011.02.004_bb0240","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid {alpha}-glucosidase. Major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2011.02.004_bb0245","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1203\/PDR.0b013e3181b24e94","article-title":"Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease","volume":"66","author":"Kishnani","year":"2009","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgme.2011.02.004_bb0250","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/GIM.0b013e31819d0996","article-title":"Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease","volume":"11","author":"Nicolino","year":"2009","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2011.02.004_bb0255","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00415-009-5275-3","article-title":"Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial","volume":"257","author":"Strothotte","year":"2009","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2011.02.004_bb0260","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.nmd.2008.04.009","article-title":"Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease","volume":"18","author":"van Capelle","year":"2008","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymgme.2011.02.004_bb0265","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/ana.20019","article-title":"Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up","volume":"55","author":"Winkel","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymgme.2011.02.004_bb0270","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10545-009-9003-z","article-title":"Diagnostic efficacy of the fluorometric determination of enzyme activity for Pompe disease from dried blood specimens compared with lymphocytes-possibility for newborn screening","volume":"33","author":"Lukacs","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2011.02.004_bb0275","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.1002\/humu.20745","article-title":"Update of the Pompe disease mutation database with 107 sequence variants and a format for severity rating","volume":"29","author":"Kroos","year":"2008","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymgme.2011.02.004_bb0280","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1212\/WNL.55.8.1122","article-title":"Juvenile and adult-onset acid maltase deficiency in France: genotype-phenotype correlation","volume":"55","author":"Laforet","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2011.02.004_bb0285","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol. Genet. Metab."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719211000473?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719211000473?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:18:34Z","timestamp":1761088714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719211000473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S1096719211000473"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2011.02.004","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pompe disease: Design, methodology, and early findings from the Pompe Registry","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2011.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}